Sulfoxone sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318779

CAS#: 144-75-2 (sodium)

Description: Sulfoxone sodium, also known Adesulfone Sodium, is an anti-leprosy drug.

Chemical Structure

img
Sulfoxone sodium
CAS# 144-75-2 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 318779
Name: Sulfoxone sodium
CAS#: 144-75-2 (sodium)
Chemical Formula: C14H14N2Na2O6S3
Exact Mass: 404.02
Molecular Weight: 448.434
Elemental Analysis: C, 37.50; H, 3.15; N, 6.25; Na, 10.25; O, 21.41; S, 21.45

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 133-65-3 (free base); 144-75-2 (sodium)  

Synonym: Diasone; Sulfoxone; Aldesulfone; Adesulfone Sodium; NSC 27222.

IUPAC/Chemical Name: sodium ((sulfonylbis(4,1-phenylene))bis(azanediyl))dimethanesulfinate

InChi Key: AZBNFLZFSZDPQF-UHFFFAOYSA-L

InChi Code: InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2

SMILES Code: O=S(C1=CC=C(NCS([O-])=O)C=C1)(C2=CC=C(NCS([O-])=O)C=C2)=O.[Na+].[Na+]

Appearance: Solid powder

Purity: >90% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS# 144-76-3 (Sulfoxone free acid) CAS# 144-75-2 (Sulfoxone sodium)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 448.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Takahashi J. [Cell replacement therapy for Parkinson's disease using iPS cells]. Rinsho Shinkeigaku. 2013;53(11):1009-12. Review. Japanese. PubMed PMID: 24291862.

2: Yoneyama M, Ogita K. Activation of neuronal regeneration signal following neuronal degeneration-involvement of microglia. Nihon Yakurigaku Zasshi. 2013 Jul;142(1):17-21. Review. PubMed PMID: 23842223.

3: Paek SY, Steinberg SM, Katz SI. Remission in dermatitis herpetiformis: a cohort study. Arch Dermatol. 2011 Mar;147(3):301-5. doi: 10.1001/archdermatol.2010.336. Epub 2010 Nov 15. PubMed PMID: 21079050.

4: Wen S, Carey KL, Nakao Y, Fusetani N, Packham G, Ganesan A. Total synthesis of azumamide A and azumamide E, evaluation as histone deacetylase inhibitors, and design of a more potent analogue. Org Lett. 2007 Mar 15;9(6):1105-8. Epub 2007 Feb 21. PubMed PMID: 17311393.

5: Schomaker JM, Bhattacharjee S, Yan J, Borhan B. Diastereomerically and enantiomerically pure 2,3-disubstituted pyrrolidines from 2,3-aziridin-1-ols using a sulfoxonium ylide: a one-carbon homologative relay ring expansion. J Am Chem Soc. 2007 Feb 21;129(7):1996-2003. Epub 2007 Jan 27. PubMed PMID: 17256932.

6: Koep S, Gais HJ, Raabe G. Asymmetric synthesis of unsaturated, fused bicyclic proline analogues through amino alkylation of cyclic bis(allylsulfoximine)titanium complexes and migratory cyclization of delta-amino alkenyl aminosulfoxonium salts. J Am Chem Soc. 2003 Oct 29;125(43):13243-51. PubMed PMID: 14570500.

7: Ozawa H, Maruyama Y. [A 50-year history of new drugs in Japan: the developments of antileprosy drugs and their epidemiological aspects]. Yakushigaku Zasshi. 2002;37(1):76-83. Japanese. PubMed PMID: 12412600.

8: Reddy LR, Gais HJ, Woo CW, Raabe G. Asymmetric synthesis of anti-homopropargylic alcohols from aldehydes and chiral sulfonimidoyl substituted bis(allyl)titanium complexes through generation and elimination of novel chiral alkylidenecarbene (dimethylamino)sulfoxonium ylides. J Am Chem Soc. 2002 Sep 4;124(35):10427-34. PubMed PMID: 12197744.

9: Bugni TS, Concepción GP, Mangalindan GC, Harper MK, James RD, Ireland CM. p-Sulfooxyphenylpyruvic acid from the red macro alga Ceratodictyon spongiosum and its sponge symbiont Haliclona cymaeformis. Phytochemistry. 2002 Jun;60(4):361-3. PubMed PMID: 12031426.

10: Harvath L, Yancey KB, Katz SI. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol. 1986 Aug 15;137(4):1305-11. PubMed PMID: 3016092.

11: Langeland T. Childhood cicatricial pemphigoid with linear IgA deposits: a case report. Acta Derm Venereol. 1985;65(4):354-5. PubMed PMID: 2413697.

12: Katz SI. "Sulfoxone (Diasone) sodium for dermatitis herpetiformis" by Cornbleet, December 1951. Commentary: Sulfoxone (Diasone) in the treatment of dermatitis herpetiformis. Arch Dermatol. 1982 Oct;118(10):805-12. PubMed PMID: 6753759.

13: Katz SI, Hertz KC, Crawford PS, Gazze LA, Frank MM, Lawley TJ. Effect of sulfones on complement deposition in dermatitis herpetiformis and on complement-mediated guinea-pig reactions. J Invest Dermatol. 1976 Dec;67(6):688-90. PubMed PMID: 1003006.

14: Peters JH, Murray JF Jr, Gordon GR. The disposition of sulfoxone and solasulfone in leprosy patients. Lepr Rev. 1975 Sep;46(3):171-80. PubMed PMID: 171530.

15: FISHER I, ORKIN M. METHEMOGLOBINEMIA ASSOCIATED WITH THE INGESTION OF DIASONE. Arch Dermatol. 1965 Sep;92:327. PubMed PMID: 14329241.

16: Fisher I, Orkin M. Methemoglobinemia associated with the ingestion of Diasone. Arch Dermatol. 1965 Sep;92(3):327. PubMed PMID: 11851261.

17: PITTMAN JA, BROWN RW, MARTINDALE WE. Endocrine effects of sulfoxone and of two nitriles as compared with amphenone. Proc Soc Exp Biol Med. 1960 Nov;105:435-8. PubMed PMID: 13736124.

18: DESFORGES JF, THAYER WW, DAWSON JP. Hemolytic anemia induced by sulfoxone therapy, with investigations into the mechanisms of its production. Am J Med. 1959 Jul;27(1):132-6. PubMed PMID: 13661194.

19: DOULL JA, RODRIGUEZ JN, DAVISON AR, TOLENTINO JG, FERNANDEZ JV. Clinical evaluation studies in lepromatous leprosy second series: isoniazid and diasone (Diamidin) isoniazid and dihydrostreptomycin also a pilot study with streptohydrazid. Int J Lepr. 1957 Jul-Sep;25(3):173-92. PubMed PMID: 13524990.

20: DOULL JA. Clinical evaluation studies in lepromatous leprosy first series: diasone (diamdin), 4-4'-diaminodiphenyl sulfone, dihydrostreptomycin. Int J Lepr. 1954 Oct-Dec;22(4):377-402. PubMed PMID: 14366785.